Aidoc announced today that it received FDA clearance for the commercial use of its triaging algorithms for pulmonary embolism.
New York-based Aidoc’s triaging and notification algorithms designed to flag and communicate incidental pulmonary embolism offers increased efficiency in prioritizing incidental critical conditions through artificial intelligence (AI), according to a news release.
The technology offers an always-on safety net for unexpected cases, adding to Aidoc’s platform of existing FDA-cleared, AI-based tools for triage with intracranial hemorrhage, c-spine fractures, large vessel occlusion and intra-abdominal free gas.
Aidoc has already received CMS reimbursement approval for its AI solution for triaging and notifications related to the suspicion of stroke, while it is continuing to work on reimbursement submissions for other AI technologies.
“There’s a reason why most AI triage solutions don’t focus on incidental findings,” Aidoc chief technology officer Michael Braginsky said in the release. “Because the prevalence of incidental findings is relatively low, the specificity of the AI must be especially high, otherwise the false positive rate will be excessive and user adoption will be negatively impacted.
“In addition, an incidental PE algorithm detects PE in non-dedicated exams, where contrast is by definition suboptimal, and there’s an extremely high variability of protocols which challenges the AI even further. It was a scientific breakthrough that our team achieved that made this possible.”